This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Bull of the Day: Hims & Hers Health (HIMS)
by Ethan Feller
Hims & Hers Health stock continues to be a market leader even amid controversy
HIMSNegative Net Change
medical
Implied Volatility Surging for Molina Healthcare Stock Options
by Zacks Equity Research
Investors need to pay close attention to MOH stock based on the movements in the options market lately.
MOHNegative Net Change
medical
MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success
by Zacks Equity Research
Merus jumps 30% in three months after its cancer combo therapy showed significant efficacy in a phase II head and neck squamous cell carcinoma study.
MRKNegative Net Change BAYRYNegative Net Change MRUSNegative Net Change VRNANegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
UnitedHealth vs. Cigna: Which Insurer to Buy Amid Sector Turmoil?
by Kaibalya Pravo Dey
CI's commercial focus and clearer outlook set it apart as UNH faces guidance pulls, CEO change and rising medical costs.
UNHPositive Net Change CINegative Net Change CNCNegative Net Change
hmo insurance medical
Bayer Wins Hormone-Free Treatment Approval for Women in the UK
by Zacks Equity Research
BAYRY secures first global approval for Lynkuet in the UK, a hormone-free treatment for menopause-related hot flashes.
NVSNegative Net Change JNJNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?
by Ekta Bagri
AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.
BMYNegative Net Change ABBVNegative Net Change
biotechnology biotechs medical pharmaceuticals
InspireMD Launches CGuard Prime Carotid Stent System in the U.S.
by Zacks Equity Research
NSPR unveils FDA-approved CGuard Prime in the United States, targeting safer carotid procedures and stroke prevention.
CORNegative Net Change NSPRNegative Net Change ITGRNegative Net Change HIMSNegative Net Change
medical medical-devices
Smart Money Going in Senior Health: Key Stocks in Elderly Care
by Urmimala Biswas
RHHBY, NVO, EW and SYK are ramping up senior care innovation as aging populations reshape global healthcare demand.
ABTNegative Net Change RHHBYNegative Net Change NVONegative Net Change MDTPositive Net Change SYKNegative Net Change EWNegative Net Change
healthcare medical medical-devices pharmaceuticals
Can Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?
by Sundeep Ganoria
LLY rides high on surging demand for Mounjaro and Zepbound, now nearly half its revenues ahead of Q2 earnings.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change
biotechs medical pharmaceuticals
Here's Why You Should Add Cencora Stock to Your Portfolio Now
by Zacks Equity Research
COR gains on strong GLP-1 and specialty drug growth, but margin pressure and fierce competition pose ongoing risks.
CVSNegative Net Change CORNegative Net Change CODXNegative Net Change WGSNegative Net Change
medical medical-devices
OptimizeRx Bets on AI and Workflow Integration: Will This Pay Off?
by Indrajit Bandyopadhyay
OPRX doubles down on AI and subscriptions, but margin mix and retention risks loom over its platform transformation.
OPRXNegative Net Change HSTMNegative Net Change DOCSPositive Net Change
medical medical-devices
3 AI-Driven Medical Device Stocks to Watch in 2025
by Sridatri Sarkar
BSX, JNJ and GEHC are leveraging AI to boost device performance, diagnostics and surgical precision in 2025.
BSXNegative Net Change JNJNegative Net Change ISRGNegative Net Change NVDAPositive Net Change GEHCNegative Net Change
medical medical-devices
Cannabis Stock Cresco Labs Plunges 24% YTD: Time to Sell or Hold?
by Sundeep Ganoria
CRLBF is down 24% YTD as U.S.-only exposure, falling margins and tighter regulations weigh on its cannabis business.
CGCNegative Net Change TLRYNegative Net Change ACBNegative Net Change CRLBFNegative Net Change
marijuana medical pot-stocks
Zacks.com featured highlights Astrana Health, KT, Upbound, Noah Holdings and DXP Enterprises
by Zacks Equity Research
ASTH, KT, UPBD, NOAH, and DXPE all boast low EV-toEBITDA ratios and rising earnings estimates, making them standout value plays.
KTPositive Net Change DXPENegative Net Change NOAHPositive Net Change UPBDNegative Net Change ASTHNegative Net Change
medical
Reasons to Add Fresenius Medical Stock to Your Portfolio Now
by Zacks Equity Research
FMS continues to gain traction on the back of acquisitions & partnerships. A tough regulatory environment raises concerns.
FMSNegative Net Change CORNegative Net Change ITGRNegative Net Change HIMSNegative Net Change
medical medical-devices
RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End
by Zacks Equity Research
Ultragenyx Pharmaceutical and Mereo BioPharma shares tumble as investors await key phase III UX143 osteogenesis data now set for release at year-end.
BAYRYNegative Net Change RARENegative Net Change VRNANegative Net Change MREONegative Net Change
biotechnology biotechs medical pharmaceuticals
Billing or Healing? UnitedHealth's HouseCalls Get a DOJ Checkup
by Kaibalya Pravo Dey
UNH faces a DOJ criminal probe over its HouseCalls billing, raising stakes for the Medicare Advantage giant.
UNHPositive Net Change MOHNegative Net Change CNCNegative Net Change
insurance medical
Pharma Companies Remain Calm Amid Fresh Tariff Threat by Trump
by Ekta Bagri
Trump revives tariff threats on pharma imports, but industry giants like LLY and JNJ stay unfazed with major U.S. investments underway.
NVSNegative Net Change RHHBYNegative Net Change JNJNegative Net Change LLYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Company News for Jul 10, 2025
by Zacks Equity Research
Companies in The News Are: AMZN, BA, PLTR, UNH
BAPositive Net Change AMZNPositive Net Change UNHPositive Net Change PLTRNegative Net Change
aerospace medical
KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?
by Zacks Equity Research
KalVista jumps 36% in a week after the FDA clears Ekterly, the first oral on-demand therapy for hereditary angioedema.
AGENPositive Net Change AMRNNegative Net Change KALVNegative Net Change TAKNegative Net Change
biotechs medical
Hologic's GYN Surgical Dominance: What's Powering the Road Ahead?
by Moumi Mondal
HOLX's GYN Surgical arm gains momentum with Fluent Pro, global expansion and strategic acquisitions fueling growth.
JNJNegative Net Change MDTPositive Net Change HOLXNegative Net Change
medical medical-devices
ABT's FreeStyle Libre 3 Plus Now Available in Canada: Stock to Rise?
by Zacks Equity Research
Abbott debuts FreeStyle Libre 3 Plus in Canada, enhancing diabetes care with the world's smallest glucose sensor.
ABTNegative Net Change BSXNegative Net Change ALGNNegative Net Change CORNegative Net Change
medical
Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
by Zacks Equity Research
CNMD stock rides high on strong recurring revenues, margin gains, and surgical product growth despite supply and cybersecurity challenges.
CNMDNegative Net Change CVSNegative Net Change CORNegative Net Change WGSNegative Net Change
medical medical-devices
Should You Continue to Hold STERIS Stock in Your Portfolio Now?
by Zacks Equity Research
STE rides on strong Healthcare and AST growth, but macro pressures and customer consolidation cloud its outlook.
CAHNegative Net Change CORNegative Net Change STENegative Net Change PAHCNegative Net Change
medical medical-devices
Is it Worth Adding Boston Scientific Stock to Your Portfolio Now?
by Zacks Equity Research
BSX rides on strong MedSurg growth and strategic acquisitions amid currency headwinds.
ABTNegative Net Change BSXNegative Net Change ALGNNegative Net Change CORNegative Net Change
medical